Advertisement

Parasitology Research

, Volume 115, Issue 3, pp 1053–1063 | Cite as

A mucin-like peptide from Fasciola hepatica induces parasite-specific Th1-type cell immunity

  • Verónica Noya
  • Natalie Brossard
  • Patricia Berasaín
  • Ernesto Rodríguez
  • Carolina Chiale
  • Daniel Mazal
  • Carlos Carmona
  • Teresa FreireEmail author
Original Paper

Abstract

Fasciolosis, caused by the liver fluke Fasciola hepatica, is a major parasitic disease of livestock that causes significant economic losses worldwide. Although drugs are effective against liver flukes, they do not prevent reinfection, and continuous treatment is costly. Moreover, resistant fluke strains are emerging. In this context, vaccination is a good alternative since it provides a cost-effective long-term prevention strategy to control fasciolosis. In this paper, we evaluate the Fhmuc peptide as a potential vaccine against fasciolosis. This peptide derives from a mucin-like protein highly expressed in the infective stage of Fasciola hepatica. Mucin-like molecules expressed by parasites can contribute to several infection processes by protecting the parasite from host proteases and recognition by the immune system. We show that the Fhmuc peptide induces Th1-like immune responses specific for F. hepatica excretion-secretion products (FhESP) with a high production of IFNγ. We also investigated whether this peptide could protect animals from infection, and present preliminary data indicating that animals treated with Fhmuc exhibited reduced liver damage compared to non-immunised animals and that this protection was associated with a recruitment of B and T lymphocytes in the peritoneum, as well as eosinophils and mature dendritic cells. These results suggest that the mucin-like peptide Fhmuc could constitute a potential vaccine candidate against fasciolosis and pave the way towards the development of vaccines against parasites.

Keywords

Fasciola hepatica Vaccine Mucin-like peptide Immune response 

Abbreviations

DCs

Dendritic cells

HLN

Hepatic lymph node

MHC

Major histocompatibility complex

Notes

Acknowledgments

We are especially thankful to the abattoirs ‘Frigorífico Carrasco’ and ‘Frigrorífico Sarubbi’ for their help with the collection of worms.

Compliance with ethical standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

This work was supported by grants from the Agencia Nacional de Investigación e Innovación (PR-FCE-2009-1-2782, ANII, Uruguay) and Comisión Sectorial de Investigación Científica (CSIC, Universidad de la República, Uruguay). VN and ER were supported by CSIC and ANII, respectively.

Supplementary material

436_2015_4834_MOESM1_ESM.pdf (218 kb)
ESM 1 Supplementary Figure 1. Immunophenotyping of lymphoid or myeloid cells from Fhmuc-immunised animals in absence of infection. Immunophenotype of splenocytes and PECs from Fhmuc-immunised (20 μg/mouse) or PBS-treated mice. The immunisation was i.p. on days 0 in Complete Freund’s adjuvant followed by two additional injections at days 14 and 28 in Incomplete Freund’s adjuvant. Three weeks after infection, animals were sacrificed and spleen, HLN or PECs were removed. Cells were stained with different fluorochrome-conjugated specific antibodies and analysed by flow cytometry. Different myeloid (A) or lymphoid (B) cell populations were evaluated. Thirty thousand events were collected and gated on FSC vs SSC dot plot. Results are shown as the percentage of cells in the spleen expressed as the mean value of eight replicates (±SD, indicated by error bars) and are representative of two different experiments. Asterisks (*) represent statistically significant differences (p < 0.05). Supplementary Figure 2. Amino acid sequence alignment of the Fhmuc peptide and the B5 peptide from cathepsin B. Sequence alignment of the Fhmuc peptide and the B5 peptide from Cathepsin B3 (GenBank accession number ABU62925.1 (sequence ISEIRDQSSTSSTWAVSSAS). The alignment was performed by ClustalW. Gaps have been inserted to maximise amino acid identity. Fully conserved residues are marked with (*), residues with strongly similar properties with (:) and weakly similar properties with (.). The B5 peptide sequence was reported by Rojas-Caraballo et al. (2014). (PDF 217 kb)

References

  1. Buscaglia C, Campo V, Frasch A, Di Noia J (2006) Trypanosoma cruzi surface mucins: host-dependent coat diversity. Nat Rev Microbiol 4:229–236CrossRefPubMedGoogle Scholar
  2. Cancela M, Ruétalo N, Dell’Oca N, da Silva E, Smircich P, Rinaldi G, Roche L, Carmona C, Alvarez-Valín F, Zaha A, Tort J (2010) Survey of transcripts expressed by the invasive juvenile stage of the liver fluke Fasciola hepatica. BMC Genomics 11:227PubMedCentralCrossRefPubMedGoogle Scholar
  3. Cancela M, Santos GB, Carmona C, Ferreira HB, Tort JF, Zaha A (2015) Fasciola hepatica mucin-encoding gene: expression, variability and its potential relevance in host-parasite relationship. Parasitology 1–9. doi: 10.1017/S0031182015001134
  4. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, de Melo AL, Caliari MV, Almeida GT, Venancio TM, Verjovski-Almeida S, Oliveira SC (2008) Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis 2(10):e308. doi: 10.1371/journal.pntd.0000308 PubMedCentralCrossRefPubMedGoogle Scholar
  5. Cervi L, Borgonovo J, Egea M, Chiapello L, Masih D (2004) Immunization of rats against Fasciola hepatica using crude antigens conjugated with Freund’s adjuvant or oligodeoxynucleotides. Vet Immunol Immunopathol 97(1-2):97–104CrossRefPubMedGoogle Scholar
  6. Claridge J, Diggle P, McCann C, Mulcahy G, Flynn R, McNair J, Strain S, Welsh M, Baylis M, Williams D (2012) Fasciola hepatica is associated with the failure to detect bovine tuberculosis in dairy cattle. Nat Commun 3:doi: 10.1038/ncomms1840
  7. Donnelly S, Stack S, O’Neill S, Sayed A, Williams D, Dalton J (2008) Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechanism involving alternatively activated macrophages. FASEB J 22:4022–4032PubMedCentralCrossRefPubMedGoogle Scholar
  8. Fairweather I (2009) Triclabendazole progress report, 2005-2009: an advancement of learning? J Helminthol 83:139–150CrossRefPubMedGoogle Scholar
  9. Fairweather I (2011) Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy? Vet Parasitol 180:133–143CrossRefPubMedGoogle Scholar
  10. Flynn R, Mulcahy G (2008) The roles of IL-10 and TGF-beta in controlling IL-4 and IFN-gamma production during experimental Fasciola hepatica infection. Int J Parasitol 38:1673–1680CrossRefPubMedGoogle Scholar
  11. Flynn R, Mannion C, Golden O, Hacariz O, Mulcahy G (2007) Experimental Fasciola hepatica infection alters responses to tests used for diagnosis of bovine tuberculosis. Infect Immun 75:1373–1381PubMedCentralCrossRefPubMedGoogle Scholar
  12. Garza-Cuartero L, Garcia-Campos A, Zintl A, Chryssafidis A, O’Sullivan J, Sekiya M, Mulcahy G (2014) The worm turns: trematodes steering the course of co-infections. Vet Pathol 51(2):385–392. doi: 10.1177/0300985813519655 CrossRefPubMedGoogle Scholar
  13. Hillyer GV (2005) Fasciola antigens as vaccines against fascioliasis and schistosomiasis. J Helminthol 79(3):241–247CrossRefPubMedGoogle Scholar
  14. Keiser J, Engels D, Büscher G, Utzinger J (2005) Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 14:1513–1526CrossRefPubMedGoogle Scholar
  15. Khan M, Sajid M, Riaz H, Ahmad N, He L, Shahzad M, Hussain A, Khan M, Iqbal Z, Zhao J (2013) The global burden of fasciolosis in domestic animals with an outlook on the contribution of new approaches for diagnosis and control. Parasitol Res 112:2421–230CrossRefPubMedGoogle Scholar
  16. Lim SK (2003) Freund adjuvant induces TLR2 but not TLR4 expression in the liver of mice. Int Immunopharmacol 3(1):115–118CrossRefPubMedGoogle Scholar
  17. Loukas A, Hintz M, Linder D, Mullin N, Parkinson J, Tetteh K, Maizels R (2000) A family of secreted mucins from the parasitic nematode Toxocara canis bears diverse mucin domains but shares similar flanking six-cysteine repeat motifs. J Biol Chem 275:39600–39607CrossRefPubMedGoogle Scholar
  18. Maizels R (2013) Toxocara canis: molecular basis of immune recognition and evasion. Vet Parasitol 193:365–374PubMedCentralCrossRefPubMedGoogle Scholar
  19. Maizels R, Tetteh K, Loukas A (2000) Toxocara canis: genes expressed by the arrested infective larval stage of a parasitic nematode. Int J Parasitol 30:495–508CrossRefPubMedGoogle Scholar
  20. McManus D, Dalton J (2006) Vaccines against the zoonotic trematodes Schistosoma japonicum, Fasciola hepatica and Fasciola gigantica. Parasitology 133:S43–S61CrossRefPubMedGoogle Scholar
  21. Molina-Hernandez V, Mulcahy G, Perez J, Martinez-Moreno A, Donnelly S, O’Neill SM, Dalton JP, Cwiklinski K (2015) Fasciola hepatica vaccine: we may not be there yet but we’re on the right road. Vet Parasitol 208(1-2):101–111. doi: 10.1016/j.vetpar.2015.01.004 PubMedCentralCrossRefPubMedGoogle Scholar
  22. Noya V, Rodríguez E, Cervi L, Giacomini C, Brossard N, Chiale C, Carmona C, Freire T (2014) Modulation of dendritic cell maturation by Fasciola hepatica: Implications of glycans and mucins for vaccine development. J Vaccines Vaccin 5(4):233. doi: 10.4172/2157-7560.1000233 Google Scholar
  23. O’Neill S, Brady M, Callanan J, Mulcahy G, Joyce P, Mills K, Dalton J (2000) Fasciola hepatica infection downregulates Th1 responses in mice. Parasite Immunol 22:147–155CrossRefPubMedGoogle Scholar
  24. Perrin C, Lepesant J, Roger E, Duval D, Fneich S, Thuillier V, Alliene J, Mitta G, Grunau C, Cosseau C (2013) Schistosoma mansoni mucin gene (SmPoMuc) expression: epigenetic control to shape adaptation to a new host. PLoS Pathog 9:e1003571PubMedCentralCrossRefPubMedGoogle Scholar
  25. Piedrafita D, Estuningsih E, Pleasance J, Prowse R, Raadsma HW, Meeusen EN, Spithill TW (2007) Peritoneal lavage cells of Indonesian thin-tail sheep mediate antibody-dependent superoxide radical cytotoxicity in vitro against newly excysted juvenile Fasciola gigantica but not juvenile Fasciola hepatica. Infect Immun 75(4):1954–1963. doi: 10.1128/IAI.01034-06 PubMedCentralCrossRefPubMedGoogle Scholar
  26. Piedrafita D, Spithill T, Smith R, Raadsma H (2010) Improving animal and human health through understanding liver fluke immunology. Parasite Immunol 32:572–581PubMedGoogle Scholar
  27. Pleasance J, Wiedosari E, Raadsma HW, Meeusen E, Piedrafita D (2011) Resistance to liver fluke infection in the natural sheep host is correlated with a type-1 cytokine response. Parasite Immunol 33(9):495–505. doi: 10.1111/j.1365-3024.2011.01305.x CrossRefPubMedGoogle Scholar
  28. Roger E, Gourbal B, Grunau C, Pierce R, Galinier R, Mitta G (2008) Expression analysis of highly polymorphic mucin proteins (Sm PoMuc) from the parasite Schistosoma mansoni. Mol Biochem Parasitol 157:217–227CrossRefPubMedGoogle Scholar
  29. Rojas-Caraballo J, Lopez-Aban J, Perez del Villar L, Vizcaino C, Vicente B, Fernandez-Soto P, del Olmo E, Patarroyo MA, Muro A (2014) In vitro and in vivo studies for assessing the immune response and protection-inducing ability conferred by Fasciola hepatica-derived synthetic peptides containing B- and T-cell epitopes. PLoS One 9(8):e105323. doi: 10.1371/journal.pone.0105323 PubMedCentralCrossRefPubMedGoogle Scholar
  30. Rojo-Vázquez F, Meana A, Valcárcel F, Martínez-Valladares M (2012) Update on trematode infections in sheep. Vet Parasitol 189:15–38CrossRefPubMedGoogle Scholar
  31. Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1–22. doi: 10.1146/annurev-immunol-100311-102839 CrossRefPubMedGoogle Scholar
  32. Swartz JM, Dyer KD, Cheever AW, Ramalingam T, Pesnicak L, Domachowske JB, Lee JJ, Lee NA, Foster PS, Wynn TA, Rosenberg HF (2006) Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood 108(7):2420–2427. doi: 10.1182/blood-2006-04-015933 PubMedCentralCrossRefPubMedGoogle Scholar
  33. Theodoropoulos G, Hicks SJ, Corfield AP, Miller BG, Carrington SD (2001) The role of mucins in host-parasite interactions: Part II - helminth parasites. Trends Parasitol 17(3):130–135CrossRefPubMedGoogle Scholar
  34. Toet H, Piedrafita DM, Spithill TW (2014) Liver fluke vaccines in ruminants: strategies, progress and future opportunities. Int J Parasitol 44(12):915–927. doi: 10.1016/j.ijpara.2014.07.011 CrossRefPubMedGoogle Scholar
  35. Van Milligen FJ, Cornelissen JB, Bokhout BA (1999) Protection against Fasciola hepatica in the intestine is highly correlated with eosinophil and immunoglobulin G1 responses against newly excysted juveniles. Parasite Immunol 21(5):243–251CrossRefPubMedGoogle Scholar
  36. Walsh K, Brady M, Finlay C, Boon L, Mills K (2009) Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J Immunol 183:1577–1586CrossRefPubMedGoogle Scholar
  37. Zimmerman GL, Kerkvliet NI, Brauner JA, Cerro JE (1983) Modulation of host immune responses by Fasciola hepatica: responses by peripheral lymphocytes to mitogens during liver fluke infections of sheep. J Parasitol 69(3):473–477CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Verónica Noya
    • 1
  • Natalie Brossard
    • 1
  • Patricia Berasaín
    • 2
  • Ernesto Rodríguez
    • 1
  • Carolina Chiale
    • 1
  • Daniel Mazal
    • 3
  • Carlos Carmona
    • 2
  • Teresa Freire
    • 1
    Email author
  1. 1.UdelaR, Facultad de MedicinaDepartamento de Inmunobiología, Group of Immunomodulation and Vaccine DevelopmentMontevideoUruguay
  2. 2.UdelaR, Facultad de Ciencias, Instituto de HigieneDepartamento de Biología Celular y Molecular, Unidad de Biología ParasitariaMontevideoUruguay
  3. 3.Udelar, Facultad de MedicinaHospital de Clínicas, Cátedra de Anatomía PatológicaMontevideoUruguay

Personalised recommendations